VIA
ALXO icon

Vident Investment Advisory’s ALX Oncology ALXO Stock Holding History

Vident Investment Advisory’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50,123
Closed -$847K – 1275
2022
Q1 		$847K Buy
50,123
+8,355
+20% +$143K 0.02% 759
2021
Q4 		$898K Buy
41,768
+17,883
+75% +$771K 0.02% 749
2021
Q3 		$1.76M Sell
23,885
-1,706
-7% -$114K 0.05% 490
2021
Q2 		$1.4M Buy
25,591
+11,020
+76% +$659K 0.04% 550
2021
Q1 		$1.07M Hold
14,571
– – 0.04% 592
2020
Q4 		$1.26M Buy
+14,571
New +$877K 0.05% 474

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vident Investment Advisory's ALXO Position: Q2 2022 in Review

Vident Investment Advisory sold out of ALX Oncology (ALXO) in Q2 2022, closing a stake of 50,123 shares — an estimated $847K sold.

Vident Investment Advisory first reported a position in ALXO in Q4 2020 and held it in 6 quarters. The position peaked at $1.76M in Q3 2021. 97 funds tracked by Wall St. Rank hold ALXO as of Q2 2022.

  • Vident Investment Advisory reported no remaining ALX Oncology position as of Q2 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 50,123 ALX Oncology shares in Q2 2022, an estimated $847K.
  • Vident Investment Advisory first reported a position in ALX Oncology in Q4 2020 and held it in 6 quarters.
  • Vident Investment Advisory's ALX Oncology position peaked at $1.76M in Q3 2021.
  • 97 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2022.

Based on Vident Investment Advisory's 13F filing for Q2 2022, filed 15 Aug 2022.